Biopharma Notes, page-2

Nice find Blackninja22, these projections even exceed ITSA's expectations...

Summary below..

Therefore, we value Antisense Therapeutics at a share price of $0.85 USD (~9x current price), under the following major assumptions: 30% chance of ATL1102 approval, 50% market penetration. Revenue per patient of $300k/year with gross profit margin 70%. Only US sales estimated and projected, 10 years of sales estimated - 2023-2032. The valuation would be higher than the above estimate provided the following: Expansion of patient population to include all DMD patients (not just non-ambulant). Higher than 50% market penetration achieved Sales lasting longer than 10 years. Expansion of approved indications (MS, ATL1103 for acromegaly). EMA approval (there is no reason why this cannot occur, company is in pre-IND meetings with the EMA in parallel to the FDA currently in preparation for a pivotal trial). From here, with approval in the US, the target price would increase to $2.55. Approval in Europe by the EMA would roughly double the target price further, to $5.10 which this valuation does not factor in. An expansion of indication to ambulant DMD patients would cause a further appreciation, although further clinical trials will likely be required. At the current price of ~$0.09, there is potential for considerable upside.